Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01371617 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study With IPI-926 in Patients With Myelofibrosis
A Phase 2 study, sponsored by Infinity Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01371617 is a Phase 2 study that has completed, run by Infinity Pharmaceuticals. The registered enrollment target is 14 participants.
The verdict
NCT01371617, a Phase 2 study, has completed, sponsored by Infinity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of IPI-926 in patients with myelofibrosis (MF) (primary myelofibrosis \[PMF\], post-polycythemia vera myelofibrosis \[post-PV MF\], or post-essential thrombocythemia myelofibrosis \[post-ET MF\]).
Interventions
- DRUG IPI-926
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01371617
The ClinicalTrials.gov registry entry for NCT01371617 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Infinity Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IPI-926 is the first listed.
NCT01371617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01371617 about?
NCT01371617 is a clinical study titled "A Phase 2 Study With IPI-926 in Patients With Myelofibrosis". The purpose of this study is to determine the safety and efficacy of IPI-926 in patients with myelofibrosis (MF) (primary myelofibrosis \[PMF\], post-polycythemia vera myelofibrosis \[post-PV MF\], or post-essential thrombocythemia myelofibrosis \[post-ET MF\]).
What is the current status of trial NCT01371617?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2011-10. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01371617?
The interventions under investigation include: IPI-926 (DRUG).
Who is sponsoring clinical trial NCT01371617?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.